Dentsply Sirona Beats Q2 EPS at $0.52 and Affirms Full-Year 2026 Guidance
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-09. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Adjusted EPS outperformance of $0.52 versus $0.36 expected and 7.1% Wellspect growth offset a 4.1% revenue decline to support Dentsply Sirona's $1.40 to $1.50 full-year EPS guidance range.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factDentsply Sirona delivered Q2 adjusted EPS of $0.52, exceeding consensus estimates of $0.36. |
| What else was confirmed? | Reported factNet revenue contracted 4.1% year-over-year, while the Wellspect Healthcare business grew 7.1%. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for XRAY yet — this is the next research task. |
| What would change the assessment? | UnknownDentsply Sirona dental consumables sales trajectory — Follow-up distributor channel feedback on dental clinic equipment order rates. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Dentsply Sirona delivered Q2 adjusted EPS of $0.52, exceeding consensus estimates of $0.36.
- · Net revenue contracted 4.1% year-over-year, while the Wellspect Healthcare business grew 7.1%.
- · Management reaffirmed full-year 2026 guidance with expected net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.
Public research record
Research framework · page evidenceCompleted event assessment
earnings beat offset by top-line revenue contraction
| Type | Claim | Scope |
|---|---|---|
| Assumption | Dentsply Sirona delivered Q2 adjusted EPS of $0.52, exceeding consensus estimates of $0.36. | 2026-09-09 |
| Interpretation | earnings beat offset by top-line revenue contraction | XRAY |
Countercase, invalidators, and sources
Cost containment and Wellspect volume expansion sustain EPS tracking toward the top of the $1.40-$1.50 range.
- · Dentsply Sirona dental consumables sales trajectory — Follow-up distributor channel feedback on dental clinic equipment order rates.
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure · 2026-09-08
What remains unresolved
- Base path
- Dentsply Sirona trades within historical valuation multiples while stabilizing core dental equipment revenues.
- Adverse path
- Dental practice capital expenditure delays prolong top-line contraction below the $3.5 billion full-year sales floor.
- Supportive path
- Cost containment and Wellspect volume expansion sustain EPS tracking toward the top of the $1.40-$1.50 range.
- · Dentsply Sirona dental consumables sales trajectory — Follow-up distributor channel feedback on dental clinic equipment order rates.this week
Evidence
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure2026-09-08
“DENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance of $3.5-3.6B in sales and $1.40-1.50 adjusted EPS. Wellspect Healthcare grew 7.1%”
Supports: Dentsply Sirona adjusted EPS was $0.52 vs $0.36 consensus, revenue fell 4.1%, Wellspect grew 7.1%, and guidance affirmed at $3.5-3.6B sales and $1.40-1.50 EPS.